Ductal carcinoma in situ screening
This article was originally published in The Gray Sheet
Executive Summary
Researchers should improve breast magnetic resonance imaging techniques to enable discrimination between non-invasive ductal carcinoma in situ (DCIS) that requires intervention, and that which can be managed more conservatively, according to a Sept. 24 National Institutes of Health "State-of-the-Science" conference statement on DCIS diagnosis and management. DCIS, a spectrum of abnormal cells confined to the breast duct, is a risk factor for invasive breast cancer. Breast MRI is more sensitive than mammography and has been used to screen for DCIS, but technological advances may be required to prevent over-detection of insignificant lesions and to better risk-stratify patients who need more aggressive treatment, the conference panel concluded at the Sept. 22-24 meeting in Bethesda, Md
You may also be interested in...
Japan Grants Global-First Approval To Zolbetuximab, 15 Other New Drugs
Astellas's first-in class CLDN18.2-targeting antibody receives its first approval worldwide, while crovalimab and a number of drugs for rare diseases also receive nods from regulators and are now awaiting reimbursement price-listing.
Hanmi-OCI Merger Hits Wall As Brothers Win Shareholder Vote, Board Seats
The planned merger of Korea's Hanmi Pharm Group with OCI Group hits a major speed bump as the two sons of Hanmi's founder and other candidates recommended by them secture board seats. But it remains to be seen how the Lim brothers will fulfil their ambitious promises.
Beauty Firms Using AI-Based Tools Could Be Subject To Health Privacy Laws In US States
Using AI-based programs to collect and store consumer information risks running afoul of new health privacy laws cropping up in US states. Lack of federal regulation or guidance on the issue is one of the biggest challenges for beauty firms deploying AI, according to Stacy Marcus, partner at Reed Smith LLP.